CRDF Comptes : Analyse IA Cardiff Oncology Inc



Comptes financiers

CRDF Financier

Cardiff Oncology Inc

$1.65

-7.3%

$-0.13

À la fermeture : Apr 21, 16:00:00 GMT-4

$1.66

0.6%

$0.01

Post-Marché: Apr 21, 17:30:28 GMT-4

Aperçu Prévision Gagner Dividendes Comptes financiers

Statistiques clés

Clôture préc.

$1.78

Prix d'ouverture

$1.77

Plage de la journée

$1.65 - $1.77

Plage de 52 semaines

$1.48 - $4.56

Volume

797.9K

Volume moyen

1.0M

Rendement en dividend

BPA (TTM)

-0.69

Capitalisation boursière

$113.4M

Qu’est-ce que CRDF ?

Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. The company is headquartered in San Diego, California and currently employs 31 full-time employees. The company went IPO on 2004-07-27. The company is leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with unmet medical need. The company is focused on clinical programs in indications, such as RAS-mutated metastatic colorectal cancer (mCRC), and in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), and triple negative breast cancer (TNBC). Its lead drug candidate, Onvansertib, is an oral, small-molecule drug candidate that is highly specific for PLK1 inhibition with a 24-hour half-life. The company has other ongoing and planned clinical trials of onvansertib: one trial (CRDF-004) in first-line treatment in patients with RAS-mutated mCRC, and investigator-initiated trials in first-line mPDAC, relapsed SCLC and unresectable locally advanced or metastatic TNBC.

Fonctionnalités

Ressources

Marché

Revenus

État de situation

Flux de trésorerie

Annuel

Trimestriellement

CRDF Revenu

Chiffres en millions de dollars américains. L'exercice financier va de février à janvier.

Breakdown	TTM	12/31/2025	09/30/2025	06/30/2025	03/31/2025	12/31/2024
Revenus	0	0	0	0	0	0
Croissance des revenus (H/H)	--	--	--	--	--	--
Coût des ventes	--	--	--	--	--	--
Bénéfice brut	--	--	--	--	--	--
Vente, Général et Administration	14	2	3	3	4	3
Recherche et développement	35	5	8	11	10	9
Frais d'exploitation	49	8	12	14	14	13
Autres revenus (charges) non opérationnels	0	0	0	0	0	0
Bénéfice avant impôts	-45	-7	-11	-13	-13	-12
Charge d'impôt sur le revenu	0	0	--	--	--	0
Bénéfice net	-45	-7	-11	-13	-13	-12
Croissance du bénéfice net	0%	-42%	-8%	18%	30%	33%
Actions en circulation (diluées)	67.43	67.43	66.87	66.52	66.52	54
Variation des actions (H-H)	25%	25%	42%	48%	49%	21%
EPS (dilué)	-0.68	-0.1	-0.16	-0.2	-0.2	-0.22
Croissance du EPS	-18%	-51%	-33%	-20%	-10%	5%
Flux de trésorerie libre	-37	-5	-10	-8	-12	-11
Flux de trésorerie libre par action	--	--	--	--	--	--
Marge brute	--	--	--	--	--	--
Marge opérationnelle	0%	0%	0%	0%	0%	0%
Marge bénéficiaire	0%	0%	0%	0%	0%	0%
Marge du flux de trésorerie libre	0%	0%	0%	0%	0%	0%
EBITDA	-48	-7	-11	-14	-14	-13
Marge EBITDA	0%	0%	0%	0%	0%	0%
D&A pour le résultat opérationnel	0	0	0	0	0	0
EBIT	-48	-7	-11	-14	-14	-13
Marge EBIT	0%	0%	0%	0%	0%	0%
Taux d'imposition effectif	0%	0%	--	--	--	0%

Follow-Up Questions

Cardiff Oncology Inc의 주요 재무제표는 무엇인가요?



최신 재무제표(Form-10K)에 따르면, Cardiff Oncology Inc의 총 자산은 $0이며, 순perte입니다.

CRDF의 주요 재무 비율은 무엇인가요?



Cardiff Oncology Inc의 유동비율은 0이고, 순이익률은 0, 주당 매출은 $0입니다.

Cardiff Oncology Inc의 매출은 부문 또는 지역별로 어떻게 나뉘나요?



Le segment de revenus le plus important est Cardiff Oncology Inc, avec un chiffre d'affaires de Novel Therapies for Cancers lors du dernier rapport de résultats. En termes géographiques, United States est le marché principal pour Cardiff Oncology Inc, avec un chiffre d'affaires de 593,000.

Cardiff Oncology Inc은 수익성이 있나요?



non, 최신 재무제표에 따르면 Cardiff Oncology Inc의 순perte은 $0입니다.

Cardiff Oncology Inc에 부채가 있나요?



non, Cardiff Oncology Inc의 부채는 0입니다.

Cardiff Oncology Inc의 발행 주식은 몇 주인가요?



Cardiff Oncology Inc의 총 발행 주식은 0주입니다.

Cardiff Oncology Inc (CRDF) Financier

Graphique du cours de l'action CRDF